Literature DB >> 33926504

Emergency surgery for splenic flexure cancer: results of the SFC Study Group database.

Nicola de'Angelis1,2, Eloy Espin3, Frederic Ris4, Filippo Landi5, Bertrand Le Roy6, Federico Coccolini7, Valerio Celentano8,9, Angela Gurrado10, Denis Pezet6, Giorgio Bianchi1, Riccardo Memeo11, Giulio C Vitali4, Alejandro Solis3, Christine Denet12, Salomone Di Saverio13, Gian Luigi de'Angelis14, Miquel Kraft3, Paula Gonzálvez-Guardiola15, Aine Stakelum16, Fausto Catena17, David Fuks12, Des C Winter16, Mario Testini10, Aleix Martínez-Pérez1.   

Abstract

BACKGROUND: The effectiveness of surgical treatment for splenic flexure carcinomas (SFCs) in emergency settings remains unexplored. This study aims to compare the perioperative and long-term outcomes of different alternatives for emergency SFC resection.
METHOD: This multicenter retrospective study was based on the SFC Study Group database. For the present analysis, SFC patients were selected if they had received emergency surgical resection with curative intent between 2000 and 2018. Extended right colectomy (ERC), left colectomy (LC), and segmental left colectomy (SLC) were evaluated and compared.
RESULTS: The study sample was composed of 90 SFC patients who underwent emergency ERC (n = 55, 61.1%), LC (n = 18, 20%), or SLC (n = 17, 18.9%). Bowel obstruction was the most frequent indication for surgery (n = 75, 83.3%), and an open approach was chosen in 81.1% of the patients. A higher incidence of postoperative complications was observed in the ERC group (70.9%) than in the LC (44.4%) and SLC groups (47.1%), with a significant procedure-related difference for severe postoperative complications (Dindo-Clavien ≥ III; adjusted odds ratio for ERC vs. LC:7.23; 95% CI 1.51-34.66; p = 0.013). Anastomotic leakage occurred in 8 (11.2%) patients, with no differences between the groups (p = 0.902). R0 resection was achieved in 98.9% of the procedures, and ≥ 12 lymph nodes were retrieved in 92.2% of patients. Overall and disease-free survival rates at 5 years were similar between the groups and were significantly associated with stage pT4 and the presence of synchronous metastases.
CONCLUSION: In the emergency setting, ERC and open surgery are the most frequently performed procedures. ERC is associated with increased odds of severe postoperative complications when compared to more conservative SFC resections. Nonetheless, all the alternatives seem to provide similar pathologic and long-term outcomes, supporting the oncological safety of more conservative resections for emergency SFCs.

Entities:  

Keywords:  Cancer; Colectomy; Emergency surgery; Mortality; Splenic flexure carcinoma; Survival

Year:  2021        PMID: 33926504     DOI: 10.1186/s13017-021-00365-0

Source DB:  PubMed          Journal:  World J Emerg Surg        ISSN: 1749-7922            Impact factor:   5.469


  18 in total

1.  Lymph node metastases in splenic flexure colon cancer: Is subtotal colectomy warranted?

Authors:  Gilles Manceau; Arnaud Mori; Armelle Bardier; Jeremy Augustin; Sylvie Breton; Jean-Christophe Vaillant; Mehdi Karoui
Journal:  J Surg Oncol       Date:  2018-09-13       Impact factor: 3.454

2.  Clinicopathologic characteristics, surgical treatment and outcomes for splenic flexure colon cancer.

Authors:  Chan Wook Kim; Ui Sup Shin; Chang Sik Yu; Jin Cheon Kim
Journal:  Cancer Res Treat       Date:  2010-06-30       Impact factor: 4.679

3.  Elective surgery for tumours of the splenic flexure: a French inter-group (AFC, SFCD, FRENCH, GRECCAR) survey.

Authors:  G Manceau; S Benoist; Y Panis; A Rault; M Mathonnet; D Goere; J J Tuech; D Collet; C Penna; M Karoui
Journal:  Tech Coloproctol       Date:  2020-01-14       Impact factor: 3.781

4.  Colon carcinoma--classification into right and left sided cancer or according to colonic subsite?--Analysis of 29,568 patients.

Authors:  F Benedix; U Schmidt; P Mroczkowski; I Gastinger; H Lippert; R Kube
Journal:  Eur J Surg Oncol       Date:  2010-12-28       Impact factor: 4.424

5.  Does the outcome of colonic flexure cancers differ from the other colonic sites?

Authors:  Irshad A Shaikh; Stuart A Suttie; Mary Urquhart; Amin I Amin; Thomas Daniel; Satheesh Yalamarthi
Journal:  Int J Colorectal Dis       Date:  2011-08-18       Impact factor: 2.571

6.  Segmental Colonic Resection Is a Safe and Effective Treatment Option for Colon Cancer of the Splenic Flexure: A Nationwide Retrospective Study of the Italian Society of Surgical Oncology-Colorectal Cancer Network Collaborative Group.

Authors:  Maurizio Degiuli; Rossella Reddavid; Fulvio Ricceri; Francesca Di Candido; Monica Ortenzi; Ugo Elmore; Claudio Belluco; Riccardo Rosati; Marco Guerrieri; Antonino Spinelli
Journal:  Dis Colon Rectum       Date:  2020-10       Impact factor: 4.585

7.  Extended right hemicolectomy and left hemicolectomy for colorectal cancers between the distal transverse and proximal descending colon.

Authors:  G Gravante; M Elshaer; R Parker; A C Mogekwu; B Drake; A Aboelkassem; E U Rahman; R Sorge; T Alhammali; K Gardiner; S Al-Hamali; M Rashed; A Kelkar; R Agarwal; S El-Rabaa
Journal:  Ann R Coll Surg Engl       Date:  2016-03-29       Impact factor: 1.891

8.  Laparoscopic segmental left colectomy for splenic flexure carcinoma: a single institution experience.

Authors:  Q Chenevas-Paule; B Trilling; P Y Sage; E Girard; J L Faucheron
Journal:  Tech Coloproctol       Date:  2019-12-13       Impact factor: 3.781

9.  Short- and long-term outcomes for patients with splenic flexure tumours treated by left versus extended right colectomy are comparable: a retrospective analysis.

Authors:  Manfred Odermatt; Najaf Siddiqi; Rose Johns; Danilo Miskovic; Omar Khan; Jim Khan; Amjad Parvaiz
Journal:  Surg Today       Date:  2013-12-04       Impact factor: 2.549

10.  Treatment of splenic flexure colon cancer: a comparison of three different surgical procedures: Experience of a high volume cancer center.

Authors:  Daniela Rega; Ugo Pace; Dario Scala; Paolo Chiodini; Vincenza Granata; Andrea Fares Bucci; Biagio Pecori; Paolo Delrio
Journal:  Sci Rep       Date:  2019-07-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.